ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY
The disclosure relates to methods for treating acute respiratory distress syndrome (ARDS), acute lung inflammation (ALI), acute lung injury and/or cardiac injury (e.g., acute cardiac injury), treating an infection, reducing pathogen burden and/or inhibiting pathogen replication by administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor. In some aspects, the subject is infected with a respiratory pathogen and has influenza, SARS, MERS or COVID-19.
1 . (canceled)
2 . A method for treating acute respiratory distress syndrome (ARDS), acute lung inflammation (ALI), or acute lung injury, comprising administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor (ARI).
3 - 6 . (canceled)
7 . The method of claim 2 , wherein the subject has an infection, and the ARDS, ALI, or acute lung injury is related to or caused by the infection.
8 . A method for treating cardiac injury related to or caused by an infection, comprising administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor (ARI).
9 . (canceled)
10 . A method for treating an infection, decreasing pathogen burden in a subject with an infection, or inhibiting pathogen replication in a subject with an infection, comprising administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor (ARI).
11 - 19 . (canceled)
20 . The method of claim 7 , wherein the infection is a viral infection
21 . The method of claim 20 , wherein the viral infection is a respiratory virus or a herpes virus.
22 . (canceled)
23 . The method of claim 21 , wherein the respiratory virus is a respiratory syncytial virus (RSV), rhinovirus, parainfluenza virus (PIV), adenovirus, metapneumovirus, enterovirus, bocavirus, influenza virus, or coronavirus.
24 - 25 . (canceled)
26 . The method of claim 23 , wherein the coronavirus is SARS-CoV-1, SARS-CoV-2, or MERS-CoV.
27 . (canceled)
28 . The method of claim 21 , wherein the herpesvirus is herpes simplex virus or cytomegalovirus.
29 . The method of claim 7 , wherein the infection is a bacterial infection, a fungal infection, or a parasitic infection.
30 . The method of claim 29 , wherein the bacterial infection is selected from the group consisting of Streptococcus pneumoniae , Group B streptococci , Group A streptococci, Staphylococcus aureus, Hemophilus influenzae, Nisseria sp., Enterococcus sp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Mycobacterium tuberculosis , and Mycobacterium avium.
31 . (canceled)
32 . The method of claim 29 , wherein the fungal infection is selected from Aspergillus sp., Blastomyces sp., and Cryptococcus sp.
33 . (canceled)
34 . The method of claim 29 , wherein the parasitic infection is selected from Pneumocystis jiroveci, Plasmodium falciparum , or Plasmodium vivax.
35 . The method of claim 7 , wherein the subject has sepsis.
36 . The method of claim 8 , wherein the subject has infection-related or infection-caused cardiomyopathy, myocarditis, or acute cardiac injury.
37 . The method of claim 8 , wherein the subject has underlying cardiomyopathy.
38 - 39 . (canceled)
40 . The method of claim 36 , wherein the acute cardiac injury is characterized by elevated troponin levels.
41 . The method of claim 8 , wherein the subject has elevated troponin levels, NTproBNP levels, and/or creatine kinase levels.
42 - 46 . (canceled)
47 . The method of claim 2 , wherein the subject has influenza, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or COVID-19.
48 - 49 . (canceled)
50 . The method of claim 2 , wherein the ARI is a compound of any one of Formulas I-III, zopolrestat, epalrestat, or a salt of any of the foregoing.
51 - 52 . (canceled)
53 . The method of claim 2 , wherein the ARI is
or a salt thereof.
54 . (canceled)